In brief
- There is no federal early-access route to psilocybin to apply for today, and a clinical trial is not one.
- On 18 April the president directed the FDA and the DEA to establish a way for eligible patients to get psychedelic drugs under the Right to Try Act.
- No rule, proposed rule, or notice creating that route has appeared, and it is not listed in the government’s inventory of rulemaking in development.
- The order sets no deadline, for any section, and it states that it creates no enforceable right.
- The FDA held its public hearing on 14 September, under a notice that excluded scheduling and legalization.
What did the executive order do?
Executive Order 14401 was signed on 18 April 2026 and published four days later at 91 FR 21709 (opens in new tab). Its five directives run from vouchers for qualifying psychedelic drug programs to a rescheduling review keyed to products that complete Phase 3 trials, and the one about getting the drugs to patients is section 2(b), which reads in full:
“The FDA and Drug Enforcement Administration shall facilitate and establish a pathway for eligible patients to access psychedelic drugs, including ibogaine compounds, under the Right to Try Act (21 U.S.C. 360bbb-0a), including any necessary Schedule I handling authorizations for treating physicians and researchers, consistent with 21 U.S.C. 823, and any applicable waiver authority under the Controlled Substances Act.”
What would it take to build this route?
The Right to Try Act of 2018 added section 360bbb-0a (opens in new tab) to the Food, Drug, and Cosmetic Act and amended no provision of the Controlled Substances Act, so psilocybin stayed in Schedule I. A physician treating a patient under it would still need a DEA registration to handle the drug, and that registration is issued against a research protocol under 21 C.F.R. 1301.18 (opens in new tab).
That is why section 2(b) asks for “any necessary Schedule I handling authorizations” for “treating physicians”, which is the order’s own acknowledgment that they are not there now. A new registration posture is made by rulemaking or by published notice, so it cannot be done quietly.
How were the vouchers issued in six days?
Section 2(a) told the FDA to issue Commissioner’s National Priority Vouchers to qualifying psychedelic drug programs, and three went out on 24 April, six days after the signature: two for psilocybin, in treatment-resistant depression and in major depressive disorder, and one for methylone, in PTSD.
They came from a pilot program the FDA was already running and had put up for public comment at 91 FR 13849 (opens in new tab) on 23 March 2026, twenty-six days before the order was signed. A voucher shortens review, but it approves nothing and moves nothing out of Schedule I. The issuance produced no Federal Register document, and it reaches this page through the dated federal timeline in the register’s United States federal entry.
| What each directive required, and what each one produced | Section 2(a), the vouchers | Section 2(b), the access route |
|---|---|---|
| What it needed | a program that already existed | a new registration posture for treating physicians |
| Where it would show | nowhere; a voucher is discretion inside an existing program | in a rule or a published notice |
| What we found | three vouchers, six days after signature | no implementing document |
The 24 April issuance is recorded in this register’s own federal entry. No Federal Register document reports it.
Is anything in the works?
Nothing creating the route has been published, and nothing is listed as under development. A monthly sweep of the Federal Register for psilocybin, psilocin, psilocyn or psychedelic since 1 January 2026 held 46 documents on 23 September, of which 40 are routine DEA supply notices, and none of the six substantive ones implements, proposes or announces the section 2(b) pathway. Because an implementing document might never say psilocybin, the search widened to “Right to Try”, 360bbb-0a, ibogaine, the order’s own name and every DEA rule and proposed rule since 18 April, and none of them creates a registration category for treating physicians.
The Unified Agenda (opens in new tab) is where agencies list the rules they are working on before those rules are published. Its 2026 edition of 14 August runs to 1,304,365 bytes, and neither it nor the Department of Health and Human Services’ agenda (opens in new tab) published beside it contains psychedelic, psilocybin, ibogaine, Right to Try or 14401. DEA’s only pending special-registration item is for telemedicine.
Where we looked
- Every psilocybin-term document since 1 January
- 46, the deduped four-term universe · 40 routine DEA supply notices · 6 substantive, none implementing
- The wider searches
- “Right to Try”: 2 · 360bbb-0a: 2 · ibogaine: 14 · the order by name: 2 · every DEA rulemaking since 18 April: 27 · none implementing
- The 2026 Unified Agenda, 1,304,365 bytes
- 0 for psychedelic, psilocybin, ibogaine, Right to Try and 14401
What happened at the 14 September hearing?
The FDA held its public hearing on the potential future therapeutic use of psychedelic drugs on 14 September, under the order, and the recording is on the agency’s own channel (opens in new tab). Access was one of its four topics, which made it the nearest thing on the public calendar to section 2(b), but its notice (opens in new tab) sought no comment on the scheduling status of any substance or on legalization, and its subject was how supervised treatment would be delivered if a product is ever approved. Written comments close on 5 October.
Section 2(b), as it stands
- Directive issued
- 18 April 2026, Executive Order 14401
- Statutory deadline
- none in the order, for any section
- Implementing document
- none published
- Enforceable right
- none; the order says so, at section 6(c)
- FDA public hearing
- held 14 September 2026
- Next dated event
- written comments close, 5 October 2026
Since April the order’s two section 2 directives have moved at different speeds, because one needed a decision the FDA could already make and the other needs a rule or a notice that has not been published, with nothing on the public schedule saying one is being written. What state drug laws do if the FDA ever approves a psilocybin medicine is the subject of its own piece.
Notes
This is not a route map, and neither are the state programs in Oregon and Colorado: Oregon’s rules bar facilitators from diagnosing and treating, and Colorado’s program sits outside the practice of medicine.
This page measures only section 2(b), by its public instruments, and the order’s other directives can run through channels that never touch the Federal Register.
The claim is absence, measured on a stated method and a dated cadence, and it is neither a claim of delinquency nor a prediction. The order sets no deadline for any section, is expressly subject to the availability of appropriations and creates no enforceable right, so no patient can compel the pathway into existence.
The April vouchers show this order can move without a Federal Register document, and two other channels went unchecked: the OIRA dashboard of rules under White House review, and agency press channels. Building the pathway may also be legally hard. We report the absence and attribute no motive.
This page does not say psychedelic drugs work. The order’s premise about clinical potential is the order’s, and stays the order’s.